DOI: https://doi.org/10.22141/2224-0586.2.81.2017.99697

The cognitive functions in patients with atrial fibrillation and various genotypes of apolipoprotein E

S.M. Stadnik

Abstract


The purpose of this study was to evaluate the relationship between carriage of allele ε4 of АРОЕ gene with cognitive functions and atrophic changes of the cerebral pulp in the patients with atrial fibrillation. We examined 61 patients (mean age 64.8 ± 8.2 years) with cognitive impairment and atrial fibrillation of varying severity. The analysis results confirm the effect of genotype АРОЕ4 on the state of cognitive functions and severity of cerebral atrophy using computed tomography. The presence of even one allele ε4 was found to impact the severity of cognitive disorders, cholesterol and lipoproteins of very low density in the blood plasma. The analysis of the morphometric characteristics revealed that in 70.5 % of patients with atrial fibrillation and investigated АРОЕ genotype cognitive disorders develop of the background of atrophic process of the brain. Correlation between the level of cognitive functioning and morphometric markers of subcortical atrophy in the groups of patients with АРОЕ4 confirms its key role in the development and progression of cognitive deficits. The results of this study allows consider АРОЕ4 as a risk factor for cognitive impairment in the patients with atrial fibrillation.


Keywords


atrial fibrillation; cognitive impairment; apolipoprotein E (APOE)

References


Алехин А.Н. Психологические проблемы в аритмологии (на модели фибрилляции предсердий) / А.Н. Алехин, Е.А. Трифонова, Д.С. Лебедев // Вестник аритмологии. — 2011. — № 63. — С. 45-54.

Емелин А.Ю. Когнитивные нарушения при цереброваскулярной болезни: Автореф. дис… д-ра мед. наук. — СПб., 2010. — 37 с.

Меллер Т.Б., Райф Э. Норма при КТ- и МРТ-исследованиях: Пер. с англ. / Под общ. ред. Г.Е. Труфанова, Н.В. Марченко. — М.: МЕДпресс-информ, 2008. — 256 с.

Рогаев Е.И. Молекулярные механизмы болезни Альц­геймера: генетический подход // Болезнь Альцгеймера и старение: от нейробиологии к терапии / Е.И. Рогаев. — М.: НЦПЗ РАМН, 1999. — С. 83-86.

Салий М.И. Некоторые особенности морфометрических характеристик головного мозга у больных c лакунарным инсультом / М.И. Салий, З.В. Салий, С.И. Шкробот // Журнал неврологии и психиатрии. — 2014. — № 12. — С. 33-37.

Cуслина З.А. Практическая кардионеврология / З.А. Cуслина, А.В. Фонякин, Л.А. Гераскина, В.Вл. Машин, Е.С. Трунова, В.В. Машин, М.В. Глебов. — М.: ИМА-ПРЕСС, 2010. — С. 205-207.

Яхно Н.Н. Нейрохимические маркеры нейродегенерации в ранней диагностике болезни Альцгеймера, сосудистой и смешанной деменции / Н.Н. Яхно, Н.Н. Белушкина, О.В. Успенская // Журнал неврологии и психиатрии. — 2010. — № 8. — С. 36-40.

Яхно Н.Н. Деменции / Н.Н. Яхно, В.В. Захаров, А.Б. Локшина, Н.Н. Коберская, Э.А. Каптарян. — М.: Медпресс-информ; 2010.

Anand S.S. Genetic variants associated with myocardial infarction riskfactorsin over 8000 individuals from five ethnic groups: The INTERHEART Genetics Study / S.S. Anand, C. Xie, G. Pare // Circ. Cardiovasc. Genet. — 2009. — Vol. 2. — P. 16-25.

Breitner J.C. APOE-epsilon4 count predicts age when prevalence of AD increases, then declines: the Cache County Study / J.C. Breitner, B.W. Wyse, J.C. Anthony // Neurology. — 1999. — Vol. 53, № 2. — P. 321-331.

Coon K.D. A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer’s disease / K.D. Coon, A.J. Myers, D.W. Craig // J. Clin. Psychiatry. — 2007. — Vol. 68, № 4. — P. 613-618.

Couzin J. Genetics. Once shunned, test for Alzheimer’s risk headed to market / J. Couzin // Science. — 2008. — Vol. 319, № 5866. — P. 1022-1023.

Crean S. Apolipoprotein E ε4 prevalence in Alzheimer’s disease patients varies across global populations: a systematic literature review and meta-analysis / S. Crean, A. Ward, C. Mercaldi // Dement. Geriatr. Cogn. Disord. — 2011. — Vol. 31. — P. 20-30.

De Carli C. Alzheimer’s disease cooperative study group. Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia / C. De Carli, G.B. Frisoni, C.M. Clark // Arch. Neurol. — 2007. — Vol. 64, № 1. — P. 108-115.

Elias P.K. Blood pressure-related cognitive decline: does age a make difference? / P.K. Elias, M.F. Elias, M.A. Robbins, M.M. Budge // Hypertension. — 2004. — Vol. 44. — P. 631-636.

Farlow M. Differential qualitative responses to rivastigmine in APOE epsilon 4 carriers and noncarriers / M. Farlow, R. Lane, S. Kudaravalli, Y. He // Pharmacogenomics J. — 2004. — Vol. 4, № 5. — P. 332-335.

He J. Differences of brain volume, hippocampal volume, cerebrovascular risk factors and APOE4 among MCI subtypes / J. He, S. Farias, O. Martinez // Arch. Neurol. — 2009. — Vol. 66, № 11. — P. 1393-1399.

Kannel W.B. Prevalence, incidence, prognosis and predisposing conditions for atrial fibrillation: population-based estimates / W.B. Kannel, Р.А. Wolf, Е.J. Benjamin // Am. J. Cardiol. — 1998. — Vol. 82(8A). — P. 2-9.

Lim Y.Y. A-beta amyloid, cognition and APOE genotype in healthy older adults / Y.Y. Lim, K.A. Ellis, D. Ames // Alzhei­mer’s and Dementia. — 2013. — № 9. — P. 538-545.

Liu Y. Apolipoprotein E polymorphism and acute ischemic stroke, a diffusion and perfusion-weighted magnetic resonance imaging study / Y. Liu, M.P. Laakso, J.O. Karonen // J. Cereb. Blood Flow Metab. — 2002. — Vol. 22, № 11. — P. 1336-1342.

Mahley R.W. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer’s di­sease / R.W. Mahley, K.H. Weisgraber, Y. Huang // Proc. Natl. Acad. Sci. —2006. — Vol. 103, № 15. — P. 5644-5651.

Mielke M.M. Interaction between vascular factors and the APOE E4 allele in predicting rate of progression in Alzhei­mer’s dementia / M.M. Mielke, J.-M. Leoutsakos, J.T. Tschanz // J. Alzheimer’s Dis. — 2011. — Vol. 26, № 1. — P. 127-134.

Niu W. The relationship between apolipoprotein E epsilon2/epsilon3/epsilon4 polymorphysms and hypertension: a meta-analysis of six studies comprising 1812 cases and 1762 controls / W. Niu, Y. Qi, Y. Qian // Hypertens. Res. — 2009. — Vol. 32. — P. 1060-1066.

Ott A. Atrial fibrillation and dementia in a population-based study. The Rotterdam Study / А. Ott, М.М. Breteler, М.С. de Bruyne, F. van Harskamp, D.E. Grobbee, А. Hofman // Stroke. — 1997. — Vol. 28(2). — Р. 316-321.

Payami H. Gender difference in apolipoprotein E-associated risk for familiar Alzheimer disease: a possible clue to the higher incidence of Alzheimer disease in women / H. Payami, S. Zareparsi, K.R. Montee // Amer. J. Hum. Genet. — 1996. — Vol. 58, № 4. — P. 803-811.

Prassopoulos P. The Size of the Intra- And Extraventricular Cerebrospinal Fluid Compartments in Children With Idiopathic Benign Widening of the Frontal Subarachnoid Space / P. Prassopoulos, D. Cavouras, S. Golfinopoulos // Neuroradio­logy. — 1995. — Vol. 37. — P. 418-421.

Roses A.D. On the discovery of the genetic association of Apolipoprotein E genotypes and common late-onset Alzheimer di­sease / A.D. Roses // J. Alzheimer’s Dis. — 2006. — Vol. 9, № 3. — P. 361-366.

Sabatini T. Regarding atrial fibrillation and cognitive function in older people / Т. Sabatini, G.B. Frisoni, P. Barbisoni, G. Bellelli, R. Rozzini, M. Trabucchi // J. Am. Geriatr. Soc. — 2000. — Vol. 48. — P. 387-390.




Copyright (c) 2017 EMERGENCY MEDICINE

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2018

 

   Seo анализ сайта